(IN BRIEF) A study by the Technical University of Munich and Harvard Medical School has shown that obesity drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) reduce the risk of hospitalization or death in patients with heart failure with preserved ejection … Read the full press release →
Posted in Business, Education, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology
Tagged cardiovascular disease, Diabetes, German Heart Center, Harvard Medical School, Health Data Utilization Act, heart failure, heart failure with preserved ejection fraction, Heribert Schunkert, HFpEF, hospitalization, JAMA, mortality reduction, Mounjaro, Nils Krüger, obesity drugs, Ozempic, partnership, Semaglutide, Technical University of Munich, tirzepatide, TUM, Wegovy